FAK inhibitors in cancer, a patent review – an update on progress-Reference-Cited by-同舟云学术

FAK inhibitors in cancer, a patent review – an update on progress

Published:2024-07-02 Issue:8 Volume:34 Page:593-610
ISSN:1354-3776
Container-title:Expert Opinion on Therapeutic Patents
language:en
Short-container-title:Expert Opinion on Therapeutic Patents

Author:

Ye Ya-Xi¹,Cao Yu-Yao²,Xu Li-Sheng¹,Wang Hai-Chao¹,Liu Xin-Hua¹³,Zhu Hai-Liang²

Affiliation:

1. Institute of Pharmaceutical Biotechnology, School of Biology and Food Engineering, Suzhou University, Suzhou, PR China

2. State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, PR China

3. School of Pharmacy, Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei, PR China

Funder

Research Initiation Fund Project of Suzhou University

Key Project of Anhui Provincial Department of Education Natural Science Research

Suzhou University Research Development Fund Project

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543776.2024.2368742

Reference89 articles.

1. FAK inhibitors in Cancer, a patent review

2. Targeting FAK in anticancer combination therapies

3. New Insights on Fak and Fak Inhibitors

4. Cancer associated fibroblast FAK regulates malignant cell metabolism

5. The roles of nuclear focal adhesion kinase (FAK) on Cancer: a focused review

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Focal adhesion kinase as a new player in the biology of onco-hematological diseases: the starting evidence;Frontiers in Oncology;2024-08-30